KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced the signing of an agreement with a global pharmaceutical company. The agreement is intended for KORU Medical to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system for use with a commercialized drug therapy.
Additionally, the project will include a close collaboration with SCHOTT Pharma and is expected to be the first of multiple joint projects with SCHOTT, allowing KORU Medical to develop a platform infusion system that can integrate with both a vial and prefilled syringe. The innovative system will be developed using KORU Medical’s infusion technology along with SCHOTT TOPPAC® prefillable polymer syringes (PFS).
“This collaboration marks another milestone in our strategy to provide the most convenient infusion experience to SCIg patients,” said Linda Tharby, President and CEO of KORU Medical. “To receive the full benefit from innovative SCIg medications, including new formats like prefilled syringes, patients need an infusion system that is easy to use, fits into their lifestyles, and can efficiently deliver the drug they have been prescribed. This next-generation infusion system is intended to facilitate easier home therapy, whether the drug is dispensed via a vial or prefilled syringe. We are excited that this project includes a close collaboration between KORU and SCHOTT Pharma.”
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
